29 August 2024 A workshop held at the International Association for the Study of Pain (IASP) World Congress has revealed significant discrepancies in clinical practice guidelines (CPGs) across countries for opioid use in chronic pain management.
Pierre Fabre Laboratories has announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. 30 August 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
US RNAi therapeutics company Alnylam Pharmaceuticals today announced what is called positive detailed results from the HELIOS-B Phase III study of vutrisiran, in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 August 2024
While it may already be one of the world’s top-selling drugs across any therapy area, Merck & Co’s Keytruda (pembrolizumab) has not been successful in every indication and combination that it has been tried in across the anti-PD-1 therapy’s vast development program in oncology. 30 August 2024
NuCana announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study steering committee. 30 August 2024
The UK government has unveiled a £400 million ($530 million) investment program aimed at enhancing clinical trials and accelerating access to new treatments through the country’s national healthcare provider. 30 August 2024
Johnson & Johnson said yesterday that it has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking the first approval of nipocalimab. 30 August 2024
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it is seeking views from interested stakeholders on proposals to update its statutory fees to ensure they continue to recover their costs. 30 August 2024
The European Commission has authorized GSK's (LSE: GSK) Arexvy (respiratory syncytial virus vaccine) for preventing lower respiratory tract disease caused by RSV in adults aged 50-59 with underlying health conditions. 30 August 2024
Finnish biotech Rokote Laboratories has partnered with 3PBioVian to produce the drug substance and product for its intranasal COVID-19 vaccine, FINCoVac 2.1, ahead of Phase I trials. 29 August 2024
Regeneron Pharmaceuticals has filed a lawsuit against Sandoz, alleging that its biosimilar to Eylea (aflibercept) infringes certain patents. 29 August 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
Celltrion’s US subsidiary has signed an agreement with pharmacy benefit managers (PBMs) Cigna Healthcare, and Express Scripts that will help expand patient access to Zymfentra (infliximab-dyyb). 29 August 2024
Roche subsidiary Genentech will lay off nearly 100 employees at its San Francisco site, according to a California Worker Adjustment and Retraining Notification (WARN) notice. 29 August 2024
A workshop held at the International Association for the Study of Pain (IASP) World Congress has revealed significant discrepancies in clinical practice guidelines (CPGs) across countries for opioid use in chronic pain management. 29 August 2024
US firm Lindy Biosciences has announced a multitarget exclusive global licensing agreement and strategic collaboration with the US subsidiary of Swiss pharma giant Novartis. 29 August 2024
Pierre Fabre Laboratories has announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. 30 August 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
US RNAi therapeutics company Alnylam Pharmaceuticals today announced what is called positive detailed results from the HELIOS-B Phase III study of vutrisiran, in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 August 2024
While it may already be one of the world’s top-selling drugs across any therapy area, Merck & Co’s Keytruda (pembrolizumab) has not been successful in every indication and combination that it has been tried in across the anti-PD-1 therapy’s vast development program in oncology. 30 August 2024
NuCana announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study steering committee. 30 August 2024
The UK government has unveiled a £400 million ($530 million) investment program aimed at enhancing clinical trials and accelerating access to new treatments through the country’s national healthcare provider. 30 August 2024
Johnson & Johnson said yesterday that it has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking the first approval of nipocalimab. 30 August 2024
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it is seeking views from interested stakeholders on proposals to update its statutory fees to ensure they continue to recover their costs. 30 August 2024
The European Commission has authorized GSK's (LSE: GSK) Arexvy (respiratory syncytial virus vaccine) for preventing lower respiratory tract disease caused by RSV in adults aged 50-59 with underlying health conditions. 30 August 2024
Finnish biotech Rokote Laboratories has partnered with 3PBioVian to produce the drug substance and product for its intranasal COVID-19 vaccine, FINCoVac 2.1, ahead of Phase I trials. 29 August 2024
Regeneron Pharmaceuticals has filed a lawsuit against Sandoz, alleging that its biosimilar to Eylea (aflibercept) infringes certain patents. 29 August 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
Celltrion’s US subsidiary has signed an agreement with pharmacy benefit managers (PBMs) Cigna Healthcare, and Express Scripts that will help expand patient access to Zymfentra (infliximab-dyyb). 29 August 2024
Roche subsidiary Genentech will lay off nearly 100 employees at its San Francisco site, according to a California Worker Adjustment and Retraining Notification (WARN) notice. 29 August 2024
A workshop held at the International Association for the Study of Pain (IASP) World Congress has revealed significant discrepancies in clinical practice guidelines (CPGs) across countries for opioid use in chronic pain management. 29 August 2024
US firm Lindy Biosciences has announced a multitarget exclusive global licensing agreement and strategic collaboration with the US subsidiary of Swiss pharma giant Novartis. 29 August 2024